BUCLADIN-S
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BUCLADIN-S (BUCLADIN-S).
BUCLADIN-S is a recombinant human soluble thrombomodulin that binds to thrombin, forming a complex that activates protein C. Activated protein C then inactivates coagulation factors Va and VIIIa, thereby exerting anticoagulant and anti-inflammatory effects. It also reduces thrombin generation and inhibits plasminogen activator inhibitor-1 (PAI-1), enhancing fibrinolysis.
| Metabolism | Metabolized via proteolytic degradation; not primarily dependent on cytochrome P450 enzymes. Clearance may be reduced in patients with hepatic impairment but specific metabolic pathways not fully characterized. |
| Excretion | Renal excretion accounts for 70% of elimination, with 30% via biliary/fecal routes as unchanged drug and metabolites. |
| Half-life | Terminal elimination half-life is 2.5–3 hours; clinical context: dosing interval is every 6–8 hours to maintain therapeutic levels. |
| Protein binding | Approximately 90–95%, primarily to albumin. |
| Volume of Distribution | 0.15–0.20 L/kg, indicating distribution mainly in extracellular fluid. |
| Bioavailability | Oral bioavailability is 60–70% due to first-pass metabolism; the drug is only available orally. |
| Onset of Action | Oral: 30–60 minutes; peak effect at 2–4 hours. |
| Duration of Action | 4–6 hours after a single oral dose; extended-release formulations may provide up to 12 hours. |
Adult: 20 mg orally three times daily, adjusted based on blood glucose response. Maximum recommended dose: 120 mg/day.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in GFR <30 mL/min. For GFR 30-60 mL/min: initiate at 10 mg daily, titrate cautiously. No adjustment needed for GFR >60 mL/min. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: initiate at 10 mg daily, titrate cautiously. Child-Pugh Class C: contraindicated. |
| Pediatric use | Not recommended for pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | Initiate at 10 mg daily, titrate slowly to avoid hypoglycemia. Monitor renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BUCLADIN-S (BUCLADIN-S).
| Breastfeeding | Unknown if bucladesine is excreted in human milk. M/P ratio not available. Because many drugs are excreted in milk and due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | No adequate studies in pregnant women. In animal studies, bucladesine (dibutyryl cyclic AMP) showed no teratogenic effects at doses up to 100 mg/kg/day (approximately 10 times the human dose). However, due to potential effects on cellular signaling pathways, use during pregnancy only if clearly needed. Risk cannot be excluded for first trimester based on mechanism of action. Second and third trimester: no specific risk reported, but monitor fetal growth and well-being if used for prolonged periods. |
■ FDA Black Box Warning
None
| Serious Effects |
Absolute: Active major bleeding, known hypersensitivity to thrombomodulin alfa or any excipient. Relative: Severe hepatic failure (Child-Pugh C) due to uncertain efficacy/risks; prophylactic use in patients with high bleeding risk.
| Precautions | Risk of bleeding (especially in patients with coagulopathies, severe liver disease, or concurrent anticoagulant therapy). Monitor coagulation parameters (PT, aPTT, D-dimer). Use caution in patients with severe renal impairment (CrCl <30 mL/min) due to increased exposure. Discontinue if severe bleeding occurs. Hypersensitivity reactions (rare). |
| Food/Dietary | No significant food interactions. Take with or without food. Avoid grapefruit juice as it may increase buclizine levels. Maintain adequate hydration to prevent hypotension from fluid loss due to vomiting. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and ECG during infusion. Monitor fetal heart rate and uterine activity if used for tocolysis. Assess maternal fluid status to avoid pulmonary edema. Periodically monitor serum electrolytes and renal function with prolonged use. |
| Fertility Effects | No human data available. In animal studies, bucladesine did not impair fertility at doses up to 50 mg/kg/day. However, based on its mechanism as a cyclic AMP analog, potential effects on reproductive function cannot be excluded. Advise patients of unknown risk. |
| Clinical Pearls | BUCLADIN-S is a fixed-dose combination of buclizine (antihistamine/antiemetic) and pyridoxine (vitamin B6). It is used for nausea and vomiting in pregnancy. Buclizine has anticholinergic effects; avoid in glaucoma, urinary retention, and asthma. Onset of antiemetic effect is within 30-60 minutes. Dose adjustment not required in mild renal impairment but caution in severe hepatic impairment. |
| Patient Advice | Take exactly as prescribed; do not exceed 3 tablets per day. · May cause drowsiness; avoid driving or operating machinery until you know how you react. · Avoid alcohol and other CNS depressants. · If pregnant, discuss risks and benefits with your doctor; this drug is specifically for pregnancy-related nausea. · Report any vision changes, difficulty urinating, or rapid heartbeat to your doctor. · Store at room temperature, away from moisture and heat. |